Summary: Protamine sulphate-induced aggregation of soluble fibrin causes an increase of turbidity in the plasma sample, which can be measured by means of kinetic turbidimetry.
Introduction
measured photometrically by Lipinski in 1968 (17) . In "., .
. . * i ui r u · * ur u A \ modifications was successful (14, 15, 18) . mers, the term soluble fibrin was established (3, 4) .
The general aim of our investigation was the sensitive Increased concentrations of solüble fibrin are an early and quantifiable determination of the soluble fibrin and sensitive indicator for hypercoagulability with aggregation in a turbidimeter or nephelometer. A increased fibpnogeä turnover (5) (6) (7) .
preliminary modification of the protamine sulphatê .
. , » * ,, A-, -i test (19) showed an adequate validity in a preceeding For routme determination of soluble fibnn, the para-^Ä ^^, 1000 patient and in these coagülation test with protamine sulphate was conno interference b flbrinogen was observed . sidered practical: After fibrin monomers are released from their complex bond with fibrinogen, the protam-The intention of the present study was to develop a ine sulphate supposedly causes Polymerisation of the new turbidimetric method for detection of the promonomers (gelation), or it may possibly induce the tamine sulphate induced aggregation of soluble fibrin Polymerisation of cömplexes (8 -10) . Depending on by systematic modification of the test conditions. This the cpncentration, either fibrin gel or tiny fibrin method should provide a simple, rapid and quantifistrands are forroed (11 -13) , or the fibrinogen can able measurement of soluble fibrin without interfereven precipitate (14-16). The resulting turbidity was ence from fibrinogen in plasma.
Materials and Methods
Citrate plasina was obtaincd by cenlrifugalion (2000g, 10 min) of blood anticoagulated with sodium cilrate (0.015 mol/1) (1:10 by vol.). Plasma triacylglyceroi and cholestcrol concenlrations were less lhan 3 g/l. Special anticoagulation was required for the radioimmunoassay of fibrinopcplidc A and the tests for fibrin(ogcn) dcgradation products. Plasma samples with high fibrinogen concentrations (3.5 to 5.4 g/l) were selected from samples taken from healthy blood donors (according to the Standards for blood donor recruitment, no leukocytosis). Further samples with high fibrinogen concentrations (4.0 and 6.5 g/l) were selected from samples from patients, not seriously ill, and most of them in ambulatory care. Criteria for selection were normal values in blood coagulation tests (thromboplastin time, partial thromboplastin time, thrombin time, antithrombin III, soluble fibrin-erythrocyte-agglutination test (20) , fibrin(ogen) degradation products). Plasma samples with high soluble fibrin concentrations were obtained by incubation of citrate plasma with thrombin (25 NIH units per 1) from Hoffmann-LaRoche, Switzerland, at 30 °C. At 0 and after 0.5, 1.0, 1.5 ... 5, 10, 15, 20, 30 minutes, thrornbin-induced fibrinogen transformation was terminated by addition of hirudin (10 000 units per 1) from Pentapharm, Switzerland. No clots were visible during the first 10 minutes of thrombin action. A serial dilution of soluble fibrin plasma was performed by diluting this soluble fibrin plasma (thrombin-treated s described) in the sarne plasma before thrombin addition.
Standards of soluble fibrin were prepared using desAA-fibrin (fibrinogen devoid of both fibrinopeptides A) from Biopool, Sweden, dissolved in l mol/1 NaBr or isotonic NaCl solution. Serial dilution of these Standards resulted in final concentrations of 5 to 1000 mg/1 after adding desAA-fibrin Solutions to plasma (100 μΐ + 900 μΐ). Methods and reagents of routine diagnosis were used to determine fibrinogen concentrations (method by Clauss), thromboplastin time, partial thromboplastin time, thrombin time, antithrombin III concentrations and fibrin(ogen) degradation products (latex agglutination test with a special anticoagulant from Wellcome, United Kingdom). (20) was used for the determination of soluble fibrin by the agglutination of fibrin monomer-coated erythrocytes (FM-Test from Boehringer Mannheim, FRG). If agglutination occurred, the sample was l :2 diluted with plasma without soluble fibrin.
Soluble fibrin-erythrocyte-agglutination-test
Fibrinopeptide A RIA: Determination of plasma fibrinopeptide A was performed radioimmunologically with the FPA-J125-RIA-Kit (Mallinckrodt, USA) after precipitation of plasma fibrinogen with bentonite (special anticoagulation with thrombin inhibitor). Turbidimetry of protamine sulphate induced soluble flbrin aggregation: For the determination of soluble fibrin, citrate plasma and buffer were preincubated; after addition of protamine sulphate, the increase in turbidity was measured kinetically in a turbidimeter. The photometer "EPOS-Analyzer 5060" from Eppendorf (FRG) was suited for a short kinetic analysis; it permits the measurement of light absorbance in the Hg^spectrum and is equipped for programmable automatic pipetting of samples, buffer and protamine sulphate Solutions. Standard procedure: 40 μΐ citrate plasma and 185 μΐ 0.1 mol/1 Tris buffer (pH 6.5, containing NaCl) were preincubated for 156 seconds at 25 °C; 25 μΐ of a 2 g/l protamine sulphate dilution were added and after 12 seconds the increase in turbidity was measured at 334 nm over a timespan of 7 seconds. The result was calculated from ΔΑ/Δΐ:ΔΑ/ιηίη = (A 19s -A I2s ) -60/7, with A 0s = addition of protamine sulphate; in printouts the absorbance values were multiplied by 10000. Analyses were performed in triplicate, and any value differing from the other t wo was discarded. , r Total volume (250 μΐ), temperature (25 °C), time of plasmabuffer-preincubation (156 s), protamine sulphate incubation (12 s) and absorbance measurement (7 s) were kept constant. The evaluation of the test conditions was performed in samples with high and low fibrinogen concentfations before and after thrombin addition (stopped by hirudin) to produce soluble fibrin.
The kinetics of protamine sulphate-induced soluble fibrin aggregation were investigated in plasma samples with a high concentration of soluble fibrin or fibrinogen by continuous measurement of the resulting turbidity after addition of protamine sulphate. Furthermore, samples with high concentrations of soluble fibrin were incubated with thrombin in excess; in other series they were treated with streptokinase from Behring (FRG) and then analysed in the soluble fibrin turbidimetry again.
In fibrinogen-fibrin-turnover (in vitro induced by thrombin) soluble fibrin was determined by the turbidimetry, by the erythrocyte agglutination-test and from the release of fibrinopeptide A. The results were compared and related to the duration of thrombin action.
Results

Evaluation of the test conditions
Wavelength
Aggregation of soluble fibrin induced by protamine sulphate causes stronger signal at shorter wavelengths, which shows a linear dependence on Hgspectrum frequency ( fig. 2 a) ; the same dependence was shown by spectrophotometry in the continuous spectrum between 800 and 330 nm (3 minutes after addition of protamine sulphate).
Kinetics
The continuous increase in turbidity after addition of protamine sulphate was measured during 140 s in 3 samples with different concentrations of soluble fibrin ( fig. 1 ). The greatest increase in turbidity ΔΑ/At was seen immediately after addition of protamine sulphate; by using a l: 2 diluted soluble fibrin-sample, the initial slope was reduced by 50%.
In a plasma sample with a high fibrinogen concentration (5.5 g/l), an increase in turbidity was also noticed after addition of protamine sulphate, but distinctly less than in a sample with a high concentration of soluble fibrin. The sample was examined before and after addition of 500 mg/1 desAA-fibrin Standard; in the sample containing desAA-fibrin the turbidity in- crease was about A = 0.0107 from the 12th to the 19th second after addition of protamine sulphate; in comparison the sample without desAA-fibrin showed an increase of only A = 0.0006 in the same timespan.
pH Value and concentrations in the assay
In order to optimize the test conditions, ΔΑ/min was examined in samples with high fibrinogen and fibrin concentrations (thrombin-induced) in dependence on the pH value and on plasma-and protamine sulphate concentration.
Maximal changes in absorbance were obtained upon buffering the test solution at pH 6.5 to 7.5 (0.1 mol/1 Tris). Above pH 7.0, high fibrinogen concentrations also caused increasing Signals. Further studies were therefore performed at pH 6.5 to 7.0 (not shown). To demonstrate the relation between the specific effect of protamine sulphate on soluble fibrin and its unspecific effect on fibrinogen, the Ordinate in figure 2d shows the quotient of 'turbidity increase in samples with high concentrations of soluble fibrin' and the 'turbidity increase in samples with high fibrinogen concentrations'. Above protamine sulphate concentrations of 0.2 g/l the fibrinogen sensitivity increased more than the soluble fibrin sensitivity ( fig. 2c-2d ).
The increase of turbidity (ΔΑ/min) was not clearly dependent on the plasma concentration in the test. Moreover, the curves were dependent on the protamine sulphate concentration (set of curves for 0.12, 0.16, 0.20, 0.24 g/l). At higher protamine suiphate concentrations, ΔΑ/min increased s the plasma concentrations in the test increased.
Sensitivity l linear ity
The results of the turbidimetric method correlated well with the concentration of soluble fibrin in a dilution series (r = 0.99, n = 8), using the soluble Fibrin plasma and plasma before thrombin treatment s diluent (fig. 2b) ; the results were linearly dependent on soluble fibrin concentrations in the r nge of ΔΑ/ min from 0.010 to 0.150; and there was also a linear relationship with the serial dilution of desAA-fibrin in plasma. l g/l desAA-fibrin resulted in a ΔΑ/min of 0.179 and 0.1 g/l in ΔΑ/min of 0.0196. Concentrations of less than 0.015 g/l desAA-fibrin were not reliably detected by the new turbidimetric method.
Reproducibility
The Plasmin (induced by addition of streptokinase) caused a slower, but fmally complete decrease without generation of fibrin Strands.
Twenty five percent of the 500 patient plasma samples with high fibrin gen concentrations (4 -7 g/l) showed no elevation of turbidity. In 58% of 34 plasma samples from obviously healthy persons (blood donors) with fibrin gen concentrations from 4 to 5.5 g/l, soluble fibrin was not elevated (ΔΑ/min < 0.004); the other 14 plasma samples yielded only slightly elevated values.(AA/min < 0.012). More than 90% of normal subjects with fibrin gen concentrations less than 4 g/l showed values in the developed method of less than ΔΑ/min = 0.004.
In a clinical study, healthy persons had distinctly lower values (mean of ΔΑ/min = 0.0022, n = 45) than patients from general care wards (mean of ΔΑ/ min = 0.0305, n = 220) and patients from intensive care wards (mean of ΔΑ/min = 0.0508, n = 598); intensive care patients suffering from bl od coag lation disorders showed very high values up to ΔΑ/min of 0.300 (mean of ΔΑ/min = 0.0885, n = 127).
The increase of fibrinopeptide A and the soluble fibrin turbidimetric values, in dependence on the duration of the in vitro thrombin ction, is shown in figure 3 (computer-aided curve). The concentrations of fibrinopeptide A described an initially linear increase, rapidly attaining high values. The results of the sol- 
Discussion
Soluble fibrin is an early and sensitive indicator of hypercoagulability with increased fibrinogen turnover (5 -7). For routine soluble fibrin diagnosis a method has been developed by systematic modifications of the test conditions. This method allows an adequately sensitive and quantitative determination of soluble fibrin by means of protamine sulphate-induced aggregation of soluble fibrin without interference from fibrinogen; the test can be performed simply and rapidly.
Evaluation of the test conditions
Light scattering
Light is diffusely reflected in colloidal Solutions; nephelometers detect scattered light directly, turbidimeters indirectly through loss of intensity. Although the nephelometer tends to be more sensitive at low turbidity, the present turbidimetric method yields more sensitive and reproducible results, through fully automatic analysis and precise kinetic measurements, than preliminary experiments with a laser-nephelometer (19) . Both turbidimetry and nephelometry allow quantitative measurements, and they are considerably more sensitive than visual estimations, which are evaluated subjectively in titres, or only descriptively.
Wavelength
In spectrophotometry the aggregation of soluble fibrin causes a stronger signal at shorter wavelengths apparently following Raleigffs law of light scattering (A = k χ frequency). Thus all further experiments were performed at 334 nm.
Recent kinetic investigations of fibrin aggregation were^also done at short wavelengths (21) (22) (23) . In coritrast, measurement at 610 nm s recommended by Lipinski (17) decreased the sensitivity. Turbidimetry of clotting in routine diagnostic tests is usually recorded at 550 nm.
Kinetics
The continuous measurement of protamine sulphateinduced turbidity (ΔΑ/At) showed the greatest increase immediately after addition of protamine sulphate. The initial velocity was proportional to soluble fibrin concentrations in plasma ( fig. 1 ), s already shown by Latallo in kinetic investigations of fibrin Polymerisation (21) . Thus further measurements were performed with both incubation (12 s) and measurement (7 s) times s short s possible (limited by the apparatus). This yields a high rate of sample analyses (30 seconds per triple measurement). Moreover the short timing is important to avoid disturbing influences of fibrinogcn.
Interpolation of 6 single values for each measurement without any movement of the cuvette in the beam results in good reproducibility, in spite of the extremely short time of measurement. The initial turbidity of the plasma sample does not affect the results during kinetic measurements. Earlier studies used endpoint measurements after 5 -10 minutes or visual estimations 15 -30 minutes after addition of protamine sulphate (11, 12, (24) (25) (26) . In some studies additional controls were performed after 24 hours, in order to avoid false positive results through precipitation of fibrinogen (11, 13) .
pH-value, protamine sulphate concentrations and plasma fractions were varied in order to establish optimal test conditions, äs in earlier studies of this kind (12, 13, 19, 21, 24, 27) .
Good results were obtained at pH 6.5 -7.0 . Buffers other than Tris, such äs phosphate or PIPES Solutions, all tested in the same manner, resulted in less soluble fibrin sensitivity or a greater fibrinogen influence. Using 0.1 mol/1 Tris at pH 6.5, the final mixture after protamine sulphate and plasma addition resulted in pH 6.7 to 6.8.
An acid pH value is intended to avoid a spontaneous Polymerisation of soluble fibrin (21, 26) . A pH value between 5.8 -7.0 leads to lateral polymerisation of soluble fibrin, which produces thick fibrils and therefore a photometrically well detectable turbidity (23, 27) . Only a few authors have used pH values outside this ränge (14, 27) .
Protamine sulphate concentrations ofO.2 g/1 were suitable. Several other authors have used protamine sulphate concentrations up to 2 g/l (14, 25) , and the effect of such concentrations on fibrinogen precipitation has been discussed controversially (10, 11, 15, 24, 29) . Gurewich also used final protamine sulphate concentrations of 0.2 g/l or less in order to avoid fibrinogen precipitation (11). Gurewich's serial dilution test with protamine sulphate concentrations of 0.5-0.06 g/l is known to be a reliable and sensitive, but time consuming protamine sulphate test for the detection of soluble fibrin (6, 30) . Even though protamine sulphate is a biological product, another preparation with protamine sulphate from Sigma (USA) performed identically.
In contrast to the linear dependency of the turbidity increase on soluble fibrin concentration in plasma ( fig.  2 b) , there was no clear cut dependency of the turbidity change /min on the plasma fraction in the final test mixture (not shown); an increase of /min in dependence on plasma concentration was noticed only in the presence of higher concentrations of protamine sulphate. The observation that a plasma concentration of 24% did not yield a two fold greater increase in turbidity than a plasma concentration of 12% might be due to the fact that not only soluble fibrin is diluted but all plasma proteins,· and albumin för example is said to have an inhibitory effect on protamine sulphate. A plasma fraction of 0.20 in the test provided better results than concentrations of 50 to 90% äs required for visual estimations by other authors (11, 12, (24) (25) (26) ).
In conclusion, wheri compared with fonner modifications with visual estimations, this new methöd for the detection of protamine sulphate^induced aggregation of soluble fibrin in a turbidimeter provides low protamine sulphate and plasma concentrations; it is characterized by a kinetic measurement over a short tirne period, also with a short incubation time. An adequately sensitive determination of soluble fibrin withô ut interference from plasma fibrinogen was possible only under these specific test conditions.
Specificity
The in vitro thrombin-induced fibrinogen-fibrin turnover was detected equally well by fibrinopeptide A RIA and soluble fibrin turbidimetry. The values obtained with both methods rose in dependence on the thrombin action up to a plateau ( fig. 3) . A small delay in the increase of turbidimetric values may be due to a lack of detectable aggregation of soluble fibrin at very low concentrations of soluble fibrin.
Apart from the correlation with the solüble fibrinerythrocyte-agglutination test, in other in vitro studies the results of the turbidimetry correlated well (n = 51, r = 0.96) with the immunological determination of soluble fibrin (31, 32) , and (n = 36, r = 0.94) with the soluble fibrin determined by the tissue plasminogen activator test (31, 33) . In addition to this correlation with the immunological and the functional test, experiments with streptokinase and thrombin supported the assumption that the turbidity is caused by a clottable fibrinogen derivative.
The absence of interference by fibrinogen was demonstrated by using plasma samples, which provided normal values in the newly developed turbidimetric methöd in spite of high fibrinogen concentrations up to 6.5 g/l. Nevertheless, high turbidimetric-values were more freqüent at high fibrinogen concentrations, thus supporting fonner assumptions on fibrinogen over (1).
The influence of plasma proteins, in particular of fibrin(ogen) degradation products (29) , plasma lipids and drugs has not yet been elucidated completely; late fibrin(ogen) degradation products apparently do not cause positive results, whereas early fibrin(ogen) degradation products are supposed to be detected; Ddimers do not seem to result in' false positive values.
Application of the new turbidimetric method
The reproducibility of the results was adequate (tab. 1). Triplicate measurements were performed in order to eliminate values differing from the other two; these were possibly due to the small volume and short time necessary. In routine diagnosis, the median was taken äs the result. In spite of the short measuring time of 7 seconds, high reproducibility is obtained by the fully automatic analysis procedure with exact pipetting and sensitive optical measurements.
The analytical procedure is simple and can also be performed by untrained laboratory personnel with a minimum of labour. Soluble fibrin results could be obtained more simply, reliably and quickly than the fibrinopeptide A RIA results.
The high rate of sample throughput, the very low cost of reagents (less than l % of Quick test) and small amount of plasma required are all criteria, which help to make this test economical, an important requirement for routine diagnosis.
In conclusion, the practicability and rapid availability of reproducible quantitative results are important criteria for the application of the newly developed turbidimetric method in determination of soluble fibrin especially in the routine diagnosis of hypercoagulability with an increased fibrinogen turnover.
